Next, we assessed the effects of MRT 68921 and SBI-0206965 on primary leukemic blasts obtained from FLT3-ITD (+) (n = 7) and FLT3-WT AML patients (n = 6) and normal CD34 (+) cells obtained from healthy donors for allogeneic stem cell transplantation (n = 5). This evidence concerns the gene CD34 and acute myeloid leukemia.